SANA
Sana Biotechnology Inc
NASDAQ: SANA · HEALTHCARE · BIOTECHNOLOGY
$3.29
+1.23% today
Updated 2026-04-30
Market cap
$877.47M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-0.96
Dividend yield
—
52W range
$2 – $7
Volume
3.1M
Sana Biotechnology Inc (SANA) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | — | — | — | — | — | — | — |
| Cost of revenue | $1000.00 | $3.92M | $10.17M | $17.91M | $27.73M | $30.86M | $15.49M | $12.75M |
| Gross profit | $-1000.00 | $-3.92M | $-10.17M | $-17.91M | $-27.73M | $-30.86M | $-15.49M | $-12.75M |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $4.01M | $119.38M | $257.88M | $306.50M | $201.00M | $219.84M | $208.68M | $131.98M |
| SG&A | $8.41M | $21.78M | $28.27M | $50.41M | $71.56M | $73.30M | $64.04M | $44.30M |
| Operating income | $-8.22M | $-141.15M | $-286.15M | $-356.91M | $-272.56M | $-293.14M | $-272.72M | $-190.96M |
| Operating margin | — | — | — | — | — | — | — | — |
| EBITDA | $-13.25M | $-138.90M | $-280.23M | $-345.84M | $-256.94M | $-268.58M | $-255.33M | $-178.21M |
| EBITDA margin | — | — | — | — | — | — | — | — |
| EBIT | $-13.25M | $-142.82M | $-286.15M | $-356.91M | $-272.56M | $-293.14M | $-272.72M | $-190.96M |
| Interest expense | $0.00 | $2.83M | $0.00 | $11.07M | $15.63M | — | — | — |
| Income tax | — | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-13.25M | $-130.78M | $-278.64M | $-344.18M | $-266.39M | $-283.25M | $-266.76M | $-244.17M |
| Net income growth (YoY) | — | -887.2% | -113.1% | -23.5% | +22.6% | -6.3% | +5.8% | +8.5% |
| Profit margin | — | — | — | — | — | — | — | — |